Developing a new vaccine platform to combat COVID-19 and future coronaviruses
Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses
This study is working on a new type of vaccine that uses tiny particles to help your body fight off COVID-19 and other coronaviruses better and for longer, so you might need fewer shots and get stronger protection against different virus strains.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11123595 on NIH RePORTER |
What this research studies
This research focuses on creating a novel vaccine technology using self-assembling nanoparticles to enhance the immune response against SARS-CoV-2 and other coronaviruses. By improving upon existing mRNA vaccine strategies, the project aims to develop vaccines that can provide stronger and longer-lasting protection with fewer doses. The approach involves designing vaccines that target conserved regions of the virus, which could help in generating a broader immune response against various strains. Patients may benefit from a more effective and accessible vaccine solution that can be rapidly deployed during pandemics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of COVID-19 infection or those who may benefit from enhanced vaccination strategies.
Not a fit: Patients who are already fully vaccinated and have no risk factors for severe COVID-19 may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide stronger immunity against COVID-19 and other coronaviruses.
How similar studies have performed: Other research has shown promising results with nanoparticle-based vaccine technologies, indicating potential for success in this novel approach.
Where this research is happening
San Francisco, United States
- J. David Gladstone Institutes — San Francisco, United States (Active)
Researchers
- Principal investigator: Hoffmann, Magnus Adrian Gero — J. David Gladstone Institutes
- Study coordinator: Hoffmann, Magnus Adrian Gero
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.